IP Library Granted Patent US 9,803,176
Granted Patent B2
US 9,803,176 · App. 13/732,204 · Granted Oct 31, 2017

Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses

Inventor: Amit Patel (Salt Lake City, UT)
C12N5/0682A61K35/51C12N5/0605C12N5/0653C12N5/0654C12N5/0655C12N5/0657C12N5/0665
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,803,176
App. No.
13/732,204
Granted
Oct 31, 2017
Kind
B2
Abstract

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

Claims (19)

1. An isolated cell prepared by a process comprising:

placing a subepithelial layer of a mammalian umbilical cord tissue in direct contact with a growth substrate; and

culturing the subepithelial layer such that the isolated cell from the subepithelial layer is capable of self-renewal and culture expansion,

wherein the isolated cell expresses at least three cell markers selected from the group consisting of CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and

wherein the isolated cell does not express NANOG and at least five cell markers selected from the group consisting of CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

2. The isolated cell of claim 1 , wherein the isolated cell expresses CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, and CD105.

3. The isolated cell of claim 1 , wherein the isolated cell does not express CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, and HLA-DR.

4. The isolated cell of claim 1 , wherein the isolated cell is positive for SOX2.

5. The isolated cell of claim 1 , wherein the isolated cell is positive for OCT4.

6. The isolated cell of claim 1 , wherein the isolated cell is positive for SOX2 and OCT4.

7. The isolated cell of claim 1 , wherein the wherein the isolated cell is capable of differentiation into a cell type selected from the group consisting of adipocytes, chondrocytes, osteocytes, cardiomyocytes, endothelial cells, and myocytes.

8. The isolated cell of claim 1 , wherein the isolated cell produces exosomes expressing CD63, CD9, or CD63 and CD9.

9. The isolated cell of claim 1 , wherein culturing comprises culturing in a culture media that is free of animal components.

10. A culture of differentiated cells derived from the isolated cell of claim 1 , wherein the culture of differentiated cells includes a cell type selected from the group consisting of adipocytes, chondrocytes, osteocytes, cardiomyocytes, endothelial cells, myocytes and combinations thereof.

11. The isolated cell of claim 1 that has been differentiated into an adipocyte cell.

12. The isolated cell of claim 1 that has been differentiated into a chondrocyte cell.

13. The isolated cell of claim 1 that has been differentiated into an osteocyte cell.

14. The isolated cell of claim 1 that has been differentiated into a cardiomyocyte cell.

15. The isolated cell of claim 1 that has been expanded into a cell culture.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2021
From: PATEL, AMIT
To: JADI CELL LLC
Reel/Frame 057544/0387 →
Continuity (3)
Provisional Application 61582070 · Dec 30, 2011
Provisional Application 61591211 · Jan 26, 2012
Related Publication 20130216505A1 · Aug 22, 2013